Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.

Abstract: The invention relates to novel composite materials based on a collagen matrix mineralized with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The claimed composite material comprises a collagen matrix which is mineralized with silicate and a calcium phosphate phase, said collagen being a recombinate collagen, collagen from Eumetazoa, sponge collagen from a sponge of the Demospongia class (horn sponges) or Calcarea (calcareous sponges), a synthetic collage analog, a collagen derivative or a mixture of said collagens.

Abstract: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL.

Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit.

Abstract: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL.

Abstract: A growth-inhibited hydroxyapatite is contained in agglomerates of prestructured collagen templates, wherein the prestructured collagen templates are denatured or broken up so that fibrillogenesis of the prestructured collagen templates is inhibited. Epitactic hydroxyapatite crystallites with a crystallite size below a critical nucleus radius are formed on the prestructured collagen templates.

Abstract: The invention relates to growth-inhibited hydroxyapatite for improving bone healing. It differs from the apatites employed to date in that it releases calcium ions and phosphate ions in physiological solutions, which, unlike traditional hydroxyapatites, it does not bind. It thereby promotes bone regeneration and bone growth. The growth-inhibited hydroxyapatite contains in agglomerates of prestructured collagen templates on which hydroxyapatite crystals with a crystallite growth of below its critical nucleus radius are formed epitactically. It is prepared by the steps a) mineralization of prestructured collagen templates in supersaturated Ca- and phosphate-ion-containing solutions, where the prestructured collagen templates are capable of diffusion and/or migration, so that HAP crystallites grow epitactically on the collagen templates and the collagen templates grown together with HAP crystallites agglomerate due to their capability of diffusion and/or migration, b) separating off the agglomerates.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

Abstract: The invention relates to a protein or peptide comprising the C?-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom.

Abstract: The invention relates to growth-inhibited hydroxyapatite for improving bone healing. It differs from the apatites employed to date in that it releases calcium ions and phosphate ions in physiological solutions, which, unlike traditional hydroxyapatites, it does not bind. It thereby promotes bone regeneration and bone growth. The growth-inhibited hydroxyapatite contains in agglomerates of prestructured collagen templates on which hydroxyapatite crystals with a crystallite growth of below its critical nucleus radius are formed epitactically. It is prepared by the steps a) mineralization of prestructured collagen templates in supersaturated Ca- and phosphate-ion-containing solutions, where the prestructured collagen templates are capable of diffusion and/or migration, so that HAP crystallites grow epitactically on the collagen templates and the collagen templates grown together with HAP crystallites agglomerate due to their capability of diffusion and/or migration, b) separating off the agglomerates.

Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

Abstract: The invention relates to novel composite materials based on a collagen matrix mineralised with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The claimed composite material comprises a collagen matrix which is mineralised with silicate and a calcium phosphate phase, said collagen being a recombinate collagen, collagen from Eumetazoa, sponge collagen from a sponge of the Demospongia class (horn sponges) or Calcarea (calcareous sponges), a synthetic collage analogue, a collagen derivative or a mixture of said collagens.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.

Abstract: The invention relates to a protein or peptide comprising the C?-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom.

Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit.

Abstract: The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.